Mallinckrodt/Epix MS-325 vascular MRI imaging agent nearing Phase II -- Epix offering prospectus.
EPIX MEDICAL MS-325 VASCULAR IMAGING AGENT PHASE II TRIALS will test the agent's ability to enhance magnetic resonance imaging of arteries and veins as an alternative to X-ray angiography, Epix Medical said in a recent initial public offering prospectus. The company believes that MS-325 may have applications in diagnosis of coronary artery disease, peripheral vascular disease and thrombosis. Epix is developing MS-325 in collaboration with Mallinckrodt.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth